Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Roivant Sciences Ltd (NASDAQ: ROIV) was $14.94 for the day, down -0.66% from the previous closing price of $15.04. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 7.14 million shares were traded. ROIV stock price reached its highest trading level at $15.125 during the session, while it also had its lowest trading level at $14.78.
Ratios:
Our analysis of ROIV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 40.54 and its Current Ratio is at 40.54. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Citigroup on September 02, 2025, initiated with a Buy rating and assigned the stock a target price of $16.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $17.Wolfe Research initiated its Outperform rating on February 15, 2024, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 22 ’25 when ERIC VENKER bought 316,182 shares for $14.99 per share.
Venker Eric bought 100,000 shares of ROIV for $1,501,339 on Sep 22 ’25. On Sep 19 ’25, another insider, ERIC VENKER, who serves as the Officer of the company, bought 683,818 shares for $14.95 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 10202252288 and an Enterprise Value of 6269068288. For the stock, the TTM Price-to-Sale (P/S) ratio is 439.18 while its Price-to-Book (P/B) ratio in mrq is 2.35. Its current Enterprise Value per Revenue stands at 269.835 whereas that against EBITDA is -5.46.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.19, which has changed by 0.27801538 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $16.05, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is 21.69%, while the 200-Day Moving Average is calculated to be 32.08%.
Shares Statistics:
ROIV traded an average of 6.78M shares per day over the past three months and 11397300 shares per day over the past ten days. A total of 682.23M shares are outstanding, with a floating share count of 431.68M. Insiders hold about 36.79% of the company’s shares, while institutions hold 64.13% stake in the company. Shares short for ROIV as of 1756425600 were 39048414 with a Short Ratio of 5.76, compared to 1753920000 on 38312269. Therefore, it implies a Short% of Shares Outstanding of 39048414 and a Short% of Float of 7.670000000000001.
Earnings Estimates
Roivant Sciences Ltd (ROIV) is presently subject to a detailed evaluation by 4.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$0.95 and -$1.56 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.3, with 4.0 analysts recommending between -$1.02 and -$1.82.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $15M to a low estimate of $1.78M. As of the current estimate, Roivant Sciences Ltd’s year-ago sales were $29.26MFor the next quarter, 8 analysts are estimating revenue of $6.46M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $1.78M.
A total of 10 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $47.2M, while the lowest revenue estimate was $2.17M, resulting in an average revenue estimate of $20.15M. In the same quarter a year ago, actual revenue was $29.05MBased on 10 analysts’ estimates, the company’s revenue will be $152.78M in the next fiscal year. The high estimate is $567.77M and the low estimate is $2.24M.
